← Back to headlines
AstraZeneca's Trial Flop Raises Concerns About Its Pipeline Value
A recent drug trial failure by AstraZeneca has prompted questions about the vulnerability of its pipeline premium, which has historically contributed to its high valuation among European pharma companies.
11 Jul, 05:00 — 11 Jul, 05:00